An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 1814
- Registration Number
- NCT00460512
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-10
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 256
- Registration Number
- NCT00458302
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 30
- Registration Number
- NCT00441168
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
Completed
- Conditions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 641
- Registration Number
- NCT00440635
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 130
- Registration Number
- NCT00431769
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 155
- Registration Number
- NCT00307684
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 753
- Registration Number
- NCT00216476
© Copyright 2024. All Rights Reserved by MedPath